Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the 2020 Fortune Best Workplaces for Millennials™ list. Horizon ranked 7th among 25 companies in the small and medium company category in its first year on the list.

Horizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is offering to sell $700,000,000 of its ordinary shares in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional $105,000,000 of ordinary shares in the public offering.

Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares

Horizon Therapeutics PLC (HZNP) CEO Timothy Walbert on Q2 2020 Results - Earnings Call Transcript

Investors were pleased with the company’s latest quarterly update.

Why Horizon Therapeutics Stock Is Up Today

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 7.50% and 26.67%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Q2 Earnings and Revenues Top Estimates

Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q2 results.

Recap: Horizon Therapeutics Q2 Earnings

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics Record Second-Quarter 2020 Results; Increased Guidance

Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full‐Year 2020 Net Sales and Adjusted EBITDA Guidance

Horizon Therapeutics (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Horizon Therapeutics (HZNP) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company has reached target patient enrollment for its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA [(MIRROR) randomized controlled trial (RCT)]. MIRROR RCT is the largest randomized trial to evaluate the efficacy and safety of the concomitant use of KRYSTEXXA® (pegloticase injection) with methotrexate as an immunomodulator to help more people with chronic g

Target Enrollment Reached in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) Co-Prescribed with Methotrexate as an Immunomodulator to Enhance Response Rates for People Living with Uncontrolled Gout

AbbVie

Eli Lilly

Novo Nordisk

Dr. Reddy's Labs

United Therapeutics

Zoetis

There’s a select group of pharmaceutical stocks that stand to win without even looking for a Covid-19 cure.
The post The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase appeared first on InvestorPlace.

The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its second-quarter 2020 financial results will be released on Wednesday, Aug. 5, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to

Horizon Therapeutics plc to Release Second-Quarter 2020 Financial Results and Host Webcast on Aug. 5, 2020

Horizon Therapeutics Looks Fairly Valued After Recent Run-Up

Boston Properties

Equity Residential

Growth focused investors may be interested in the following stocks, as their price-earnings ratios are below 20 and their earnings per share have grown significantly over the past year.

These 3 Growth Stocks Could Hold Value

Horizon Therapeutics (HZNP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Horizon Therapeutics (HZNP) Stock a Solid Choice Right Now?

Amedisys

BioMarin Pharmaceutical

Haemonetics

Zimmer Biomet Hlds

With the first half of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the second half of the year, with what should be an improving economy as we emerge from the COVID-19 pandemic lockdowns.

Jefferies 5 High-Conviction Health Care Stocks to Buy for the Second Half

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Why Is Horizon Therapeutics (HZNP) Up 13.2% Since Last Earnings Report?

American Airlines

Delta Air Lines

Southwest Airlines

United Continental Hlds

Seven Investing Lessons From Buffett's Sale Of Airlines

Horizon Therapeutics (HZNP) beat on earnings and sales in the first quarter of 2020. The company lifts net sales guidance for the full year.

Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

Horizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q1 2020 Results - Earnings Call Transcript

Investors were impressed with the company’s first-quarter financial results.

Why Horizon Therapeutics Is Soaring Today

Horizon Therapeutics crushed first-quarter estimates and raised its 2020 outlook Wednesday — pushing HZNP stock into a breakout.

How A First-Quarter Surprise Prodded This Biotech Into A Breakout

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 91.30% and 25.28%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Surpasses Q1 Earnings and Revenue Estimates

ACADIA Pharma

Allogene Therapeutics Inc

Alnylam Pharmaceuticals

Alexion Pharma

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates

Horizon Therapeutics (HZNP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Horizon Therapeutics: A Classic Value Play In The Biopharma Sector

News for Horizon Pharma Stock (HZNP)